Compare drug alternatives

Saxenda® Alternatives

Saxenda®(liraglutide)
Wegovy®(semaglutide)
Prescription Only
Saxenda (liraglutide) is used to aid weight loss and maintain weight reduction in adults dealing with obesity or overweight issues along with weight-related medical conditions....
Prescription Only
Wegovy (semaglutide) injection is a prescribed medication utilized for weight loss in obese adults, adolescents, and overweight adults with weight-related health concerns. It...
Dosage & Administration
Administration
Subcutaneous. Learn more.
Subcutaneous. Learn more.
Dosing
The recommended dose of SAXENDA® is 3 mg daily. Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached.. Learn more.
Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached. The maintenance dosage of WEGOVY® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Learn more.
Latin Shorthand
3 mg daily. Start: 0.6 mg/day for 1 week. Weekly increments to reach 3 mg dosage.. Learn more.
Begin at 0.25 mg qw for 4w. Increase by 4-week intervals until reaching 2.4 mg. The maintenance dosage for adults using WEGOVY® is either 2.4 mg (recommended) or 1.7 mg qw... Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
$225 per fill. Learn more.
Assistance Expiration
12/31/2023. Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis. . Learn more.
Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. . Learn more.
Mechanism of Actions (MoA)
GLP-1 Receptor Agonists. Learn more.
GLP-1 Receptor Agonists. Learn more.
Special Populations
Is SAXENDA® safe during pregnancy?

SAXENDA® is contraindicated during pregnancy as weight loss offers no benefit and may harm the fetus. There's limited data on its use in pregnant women.

What do animal studies reveal about liraglutide's effects during pregnancy?

Animal studies have shown increased adverse effects on embryofetal development due to liraglutide exposure during pregnancy, indicating potential harm.

Are there data on the use of SAXENDA® during lactation?

There's no data on the presence of liraglutide in human milk, but it was detected in lactating rat milk. Consider breastfeeding benefits and potential risks of SAXENDA® for both mother and infant.

Is SAXENDA® approved for pediatric use?

SAXENDA® is approved for pediatric patients aged 12 years and older with obesity, supported by clinical trials. However, some adverse events were reported in these trials.

How does SAXENDA® perform in geriatric patients?

In clinical trials, no significant differences were observed in safety or effectiveness between older and younger patients. However, caution is advised in the elderly.

What precautions should be taken for patients with renal impairment using SAXENDA®?

Limited experience exists for SAXENDA® in patients with renal impairment. There have been reports of renal failure, necessitating caution in this population.

How about the use of SAXENDA® in patients with hepatic impairment?

Limited experience exists for SAXENDA® in patients with hepatic impairment, indicating caution in this patient population.

Is SAXENDA® suitable for patients with pre-existing gastroparesis?

SAXENDA® has not been studied in patients with pre-existing gastroparesis.

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null